MBA MPH - Xenon Pharmaceuticals Chief Officer
| XENE Stock | USD 40.47 0.28 0.70% |
Insider
MBA MPH is Chief Officer of Xenon Pharmaceuticals
| Age | 43 |
| Phone | 604 484 3300 |
| Web | https://www.xenon-pharma.com |
Xenon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1892) % which means that it has lost $0.1892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2671) %, meaning that it created substantial loss on money invested by shareholders. Xenon Pharmaceuticals' management efficiency ratios could be used to measure how well Xenon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ashish MBA | Vaxcyte | 53 | |
| Prof Shair | Nuvalent | 56 | |
| James Spudich | Cytokinetics | 83 | |
| Jonathan MBA | Viridian Therapeutics | 49 | |
| FAAD MBA | AnaptysBio | 47 | |
| BS CPA | Inhibrx | 42 | |
| Sven MD | Merus BV | 62 | |
| Harry Shuman | Merus BV | N/A | |
| Kevin Capps | Crinetics Pharmaceuticals | N/A | |
| Paul Stone | Ideaya Biosciences | 60 | |
| Prof MD | Ventyx Biosciences | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 67 | |
| Rob Henderson | Viridian Therapeutics | N/A | |
| Stephanie Yao | Kronos Bio | N/A | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Cornelis Kruif | Merus BV | 60 | |
| Marvin Caruthers | Viridian Therapeutics | 85 | |
| Lara Meisner | Viridian Therapeutics | 50 | |
| Jeffrey Hager | Ideaya Biosciences | 59 | |
| Charles Newton | Lyell Immunopharma | 54 | |
| Susanna MBA | Dyne Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 |
Xenon Pharmaceuticals Leadership Team
Elected by the shareholders, the Xenon Pharmaceuticals' board of directors comprises two types of representatives: Xenon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenon. The board's role is to monitor Xenon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xenon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CMA CPA, CEO Pres | ||
| MBA MPH, Chief Officer | ||
| Sherry Aulin, Chief Officer | ||
| Christopher MD, Chief Officer | ||
| Andrea JD, Chief Secretary | ||
| Robin Sherrington, Sr. VP of Bus. and Corporate Devel. | ||
| MBA MSc, Ex Operations | ||
| Shelley BA, Executive Resources | ||
| James Empfield, Senior Vice President - Drug Discovery |
Xenon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xenon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 2.44 B | ||||
| Shares Outstanding | 76.24 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 99.63 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 3.87 X | ||||
| Price To Sales | 181.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.